

December 17, 2002

Name of the Company: Yamanouchi Pharmaceutical Co., Ltd. (the “Company”)
Name of Representative: Toichi Takenaka, President & Representative Director
(Securities Code No.:4503)
Stock Exchange(s) where the Company’s
Shares are listed in Japan: The First Section of each of the Tokyo Stock Exchange,
the Osaka Securities Exchange, the Nagoya Securities
Exchange and the Sapporo Securities Exchange)

NOTICE REGARDING PURCHASE OF THE COMPANY’S OWN SHARES IN THE MARKET

You are hereby notified that the Company has implemented purchases of shares of the Company in the market for the acquisition of its own shares pursuant to the provisions of Article 210 of the Commercial Code of Japan.

Particulars

1. Purchase period: From November 7, 2002 to December 13, 2002
2. Number of shares purchased: 2,000,000 shares
3. Aggregate amount of purchase costs: ¥6,597,568,000
4. Method of the purchases: Purchases on the Tokyo Stock Exchange

(Reference 1) Contents of the resolution of the ordinary general meeting of shareholders held on June 27, 2002

*Class of shares to be acquired: Common stock of the Company

*Total number of shares to be acquired: 10,000,000 shares (Maximum)

*Aggregate amount of acquisition costs: ¥37,500,000,000 (Maximum)

(Reference 2) Aggregate number of the Company’s shares purchased on or after the date of resolution of the ordinary general meeting of shareholders (June 27, 2002)

*Total number of shares purchased: 6,000,000 shares

*Aggregate amount of purchase costs: ¥18,327,476,000

(Reference 3) Aggregate number of the Company’s shares purchased on or after the date when the “Law regarding the Partial Amendments, etc. to the Commercial Code, etc. of Japan” (Law No. 79, 2001) was enforced (October 1, 2001)

*Number of shares purchased: 26,000,000 shares

*Aggregate amount of purchase costs: ¥87,817,660,640

- End -